BD Simplifies At-Home HPV Testing to Broaden Access to Cervical Cancer Screening Outside United States

Core Insights - BD (Becton, Dickinson and Company) has announced a new self-collection solution for HPV testing aimed at enhancing cervical cancer screening accessibility globally [1][5]. Product Features - The new swab technology is certified under the In Vitro Diagnostic Medical Device Regulation (IVDR) in Europe, ensuring safety and simplicity for patients [2]. - The self-collection process is non-invasive, requiring no liquids or complex devices, and allows for easy mailing of samples from home to the lab [2][6]. - The BD COR™ System automates lab processing, eliminating manual sample preparation and enhancing laboratory efficiency [3][4]. Market Impact - The BD Onclarity™ HPV Self-Collection solution is expected to be commercially available in IVDR-recognized markets soon, supporting public health initiatives for cervical cancer screening [5]. - The innovation aims to improve participation in screening programs, particularly for underserved populations [4][5]. Company Overview - BD is a leading global medical technology company with over 70,000 employees, dedicated to advancing health care through innovative technologies and solutions [5].